United Therapeutics CEO Martine Rothblatt Sells $5,700,856 of Stock Under Trading Plan
United Therapeutics Chairman and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares for $5,700,856 under a prearranged trading plan, according to a Form 4 filing made Monday.
The Oct. 30 transactions were made through family trusts. Rothblatt exercised options at $117.76 a share and sold the 9,500 shares in multiple trades for an average of $600.09 a share, by IDD's calculation.
The exercise and sale were made under a Rule 10b5-1 trading plan Rothblatt adopted on Nov. 7, 2025. The plan runs until the earlier of the exercise of 1,734,410 stock options, all expiring March 15, 2027, or Dec. 31, 2026, according to the filing.
Holdings after the sale
After the trades, the family trust that made the sale holds 324,443 shares and 119,410 options from the exercised tranche. Rothblatt also reports 40,513 shares held directly, 166 shares held by her spouse and 303,606 shares across three other family trusts, by IDD's calculation.
By the numbers
- 9,500 options exercised at $117.76
- 9,500 shares sold on Oct. 30
- $5,700,856 total sale value
- 324,443 shares held by the selling trust afterward
Sources
- Martine Rothblatt Form 4, filed Nov. 2, 2026 (accession 0001106578-26-000176)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.